Prismic Pharmaceuticals, Inc. Acquires Scarista’s Exclusive License to Amarin’s Omega-3 Patents for CNS Disorders

SCOTTSDALE, Ariz., Feb. 7, 2012 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based, emerging pharmaceutical company, today announced that it has completed the acquisition of the assets of Scarista Limited. In particular, Prismic has acquired Scarista’s exclusive license from Amarin Neuroscience Limited, a wholly owned subsidiary of Amarin Corporation, to develop, market, and out-license products based on a portfolio of issued U.S. and foreign composition and use patents covering highly purified forms of Omega-3 fatty acids alone or in combination with other molecules for the treatment of disorders of the central nervous system (CNS).

Commenting on this acquisition, Peter Moriarty, the Chairman and co-founder of the company, stated, “This is an important milestone in the development of Prismic Pharmaceuticals. Having gained access to the robust patents through the acquisition of Scarista, Prismic is planning to partner with one or more pharmaceutical companies in order to maximize the considerable commercial opportunity the patents offer in the CNS area.”

“There is already an established body of research and clinical experience indicating the therapeutic benefits and safety of highly purified forms of EPA and DHA for the treatment of cardiovascular disease. There is also similar data relating to their use in the treatment of a number of CNS disorders,” Moriarty added. “Prismic, therefore, believes that any company licensing our IP will have the opportunity to bring patent-protected formulations to market relatively expeditiously.”

About Prismic Pharmaceuticals, Inc.

Prismic Pharmaceuticals, Inc., is a privately held pharmaceutical company focused on the development and marketing of novel prescription pharmaceuticals for psychiatric and neurodegenerative disorders, and prescription medical foods for the clinical dietary management of the metabolic processes associated with disorders of the central nervous system. The company is based in Scottsdale, Arizona, and was founded in 2011. Contact 480.422.1810 or visit www.PrismicPharma.com

INFORMATION CONTACT
Peter Moriarty
Tel: 480.422.1810

SOURCE Prismic Pharmaceuticals, Inc.

MORE ON THIS TOPIC